KLK3 and colorectal carcinoma: There is a growing expectation that the new generation of screening tests based on molecular biomarkers present in blood should improve patient compliance in CRC screening as evidenced by the success of other screening programs such as cholesterol/lipids and prostate specific antigen (PSA).[38, 39] Our approach has a great potential as a novel and promising minimally-invasive test requiring as little as 1.6 ml plasma that can be routinely introduced to hospital labs or prescribed by general practitioners.